Keman Zhang
Overview
Explore the profile of Keman Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Freitas J, Thakur V, LaPorte K, Thakur V, Flores B, Caicedo V, et al.
J Exp Clin Cancer Res
. 2024 Nov;
43(1):295.
PMID: 39491031
Background: Immune checkpoint inhibitors (ICI) have dramatically improved the life expectancy of patients with metastatic melanoma. However, about half of the patient population still present resistance to these treatments. We...
2.
Zakeri A, Zhang K, Wang L
STAR Protoc
. 2024 Aug;
5(3):103222.
PMID: 39088325
Arginase1 (ARG1) is a metabolic enzyme that is highly expressed in tumor-associated myeloid-derived suppressor cells (MDSCs) and causes the dysfunction of tumor-reactive T cells. Here, we present a protocol for...
3.
Ta H, Roy D, Zhang K, Alban T, Juric I, Dong J, et al.
Sci Immunol
. 2024 May;
9(95):eadi7418.
PMID: 38758807
Immune checkpoint blockade is a promising approach to activate antitumor immunity and improve the survival of patients with cancer. V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune...
4.
Zhang K, Zakeri A, Alban T, Dong J, Ta H, Zalavadia A, et al.
Cell Rep
. 2024 Jan;
43(1):113661.
PMID: 38175754
Myeloid-derived suppressor cells (MDSCs) impair antitumor immune responses. Identifying regulatory circuits during MDSC development may bring new opportunities for therapeutic interventions. We report that the V-domain suppressor of T cell...
5.
Pagliuca S, Gurnari C, Zhang K, Kewan T, Bahaj W, Mori M, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499220
The V-domain Ig suppressor of T-cell activation (VISTA) has been recognized as a critical negative regulator of antitumor immune response and is gaining growing interest as a potential pharmacological target...
6.
Wong D, Roy N, Zhang K, Anukanth A, Asthana A, Shirkey-Son N, et al.
Nat Commun
. 2022 Jan;
13(1):217.
PMID: 35017485
B cell-activating factor (BAFF) binds the three receptors BAFF-R, BCMA, and TACI, predominantly expressed on mature B cells. Almost all B cell cancers are reported to express at least one...
7.
Thakur V, de Freitas J, Li Y, Zhang K, Savadelis A, Bedogni B
PLoS One
. 2021 Jul;
16(7):e0253062.
PMID: 34237080
Radiotherapy remains a mainstay of treatment for a majority of cancer patients. We have previously shown that the membrane bound matrix metalloproteinase MT1-MMP confers radio- and chemotherapy resistance to breast...
8.
Vicioso Y, Wong D, Roy N, Das N, Zhang K, Ramakrishnan P, et al.
Front Immunol
. 2021 May;
12:652786.
PMID: 33995369
Natural Killer (NK) cells are cytotoxic lymphocytes critical to the innate immune system. We found that germline deficiency of NF-κB c-Rel results in a marked decrease in cytotoxic function of...
9.
Zhang K, Roy N, Vicioso Y, Woo J, Beck R, de Lima M, et al.
Oncoimmunology
. 2021 Mar;
10(1):1893501.
PMID: 33747637
Mantle cell lymphoma (MCL) is an aggressive form of B cell non-Hodgkin's lymphoma and remains incurable under current treatment modalities. One of the main reasons for treatment failure is the...
10.
Vicioso Y, Gram H, Beck R, Asthana A, Zhang K, Wong D, et al.
Cancer Immunol Res
. 2019 May;
7(7):1106-1119.
PMID: 31138521
Drug-resistant acute lymphoblastic leukemia (ALL) patients do not respond to standard chemotherapy, and an urgent need exists to develop new treatment strategies. Our study exploited the presence of B-cell activating...